Company News

“Live-Topical” Acne Treatment In Phase 2 Clinical Testing

What is AOBiome's B244 all about?

Author Image

By: Christine Esposito

Editor-in-Chief

AOBiome, Cambridge, MA, has begun a Phase 2 clinical trial with a therapeutic product candidate based on its proprietary ammonia oxidizing bacteria (AOB) for the treatment of mild to moderate acne vulgaris. The trial is being conducted under an IND application to the FDA and is the first to test the potential of live bacteria to treat skin disease. ”B244 is classified as a ‘live-topical’, a brand new class of therapeutics to address skin diseases that capitalize on advances in understanding of ...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters